Knudtzon J
Acta Paediatr Scand. 1986 May;75(3):353-61. doi: 10.1111/j.1651-2227.1986.tb10215.x.
Considerable progress has been made in the diagnosis and treatment of growth hormone-related short stature. Knowledge about growth hormone releasing factor (GRF) and somatomedin C has provided the possibility of distinguishing between hypothalamic and pituitary growth hormone deficiency and growth hormone resistance. It has been shown that treatment with GRF may stimulate growth in certain cases of growth hormone deficiency. Recombinant DNA techniques may, in the near future, provide sufficient amounts of GRF, growth hormone and possibly somatomedin C for clinical use. At present, many countries have prohibited the use of human pituitary growth hormone due to a possible risk of transmission of Creutzfeldt-Jakob disease. It has become increasingly clear that several short children without classical growth hormone deficiency, may increase their growth velocity during growth hormone treatment. There are many medical, psychological, ethical and economical implications involved in the extended treatment of children with short stature. It is necessary to maintain a restricted approach towards the treatment of children with short stature, and such treatment should be prescribed and controlled by a limited number of well-trained paediatric endocrinologists. This article reviews some of the present knowledge in this rapid developing field of paediatric endocrinology.
在生长激素相关的身材矮小症的诊断和治疗方面已经取得了相当大的进展。关于生长激素释放因子（GRF）和生长调节素C的知识，为区分下丘脑性和垂体性生长激素缺乏症以及生长激素抵抗提供了可能。研究表明，在某些生长激素缺乏症病例中，使用GRF治疗可能会刺激生长。重组DNA技术可能在不久的将来提供足够数量的GRF、生长激素以及可能的生长调节素C用于临床。目前，由于存在传播克雅氏病的潜在风险，许多国家已禁止使用人垂体生长激素。越来越明显的是，一些没有典型生长激素缺乏症的矮小儿童，在生长激素治疗期间可能会提高其生长速度。身材矮小儿童的长期治疗涉及许多医学、心理、伦理和经济问题。有必要对身材矮小儿童的治疗采取谨慎的方法，并且这种治疗应由少数训练有素的儿科内分泌学家进行处方和控制。本文综述了这个快速发展的儿科内分泌学领域的一些现有知识。
